June 2020 - 27 articles
The management of primary and secondary malignancies of the peritoneum continues to pose a challenge to modern, multidisciplinary cancer care.[...]
Background: The steady decline in breast cancer (bca) mortality has come at the cost of increasingly toxic and expensive adjuvant therapies. Trials evaluating the addition of 2 or 3 years of cyclin-dependent kinase 4/6 (cdk4/6) inhibitors to adjuvant...
Background: Multiple immunologic parameters have provided useful prognostic and assessment significance in various cancers, including head-and-neck squamous cell carcinoma (scc). We sought to identify whether pretreatment inflammatory markers could p...
Dyspnea is a symptom commonly experienced by cancer patients that causes significant suffering, worsens throughout a patient’s disease trajectory, and can be more difficult to manage than other symptoms. Assessment of dyspnea is best accomplished by...
Objective: The purpose of the present review was to provide evidence-based guidance about the provision of cytoreductive surgery (crs) with hyperthermic intraperitoneal chemotherapy (hipec) in the treatment of peritoneal cancers. Methods: The guideli...
Introduction: Standard treatment for early-stage invasive breast cancer (bca) consists of breast-conserving surgery and several weeks of adjuvant radiotherapy (rt). Neoadjuvant single-fraction rt is a novel approach for early-stage bca. We sought to...
Since January 2020, the outbreak of the novel coronavirus disease designated covid-19 by the World Health Organization, a human-to-human contagious viral pneumonia that began in 2019, has been extensively influencing daily life in China[...]
The evolving covid-19 pandemic is placing tremendous pressure on health systems. [...]
Chronic lymphocytic leukemia (cll) is the most common adult leukemia in the Western world. Unfortunately, affected patients are often immunosuppressed and at increased risk of infection and secondary malignancy. Previous meta-analysis has found that...
Background: Chemotherapy-induced T cell dysfunction, resulting from treatment of multiple myeloma (MM), enhances the risk for reactivation of latent tuberculous infection (LTBI). However, routine screening for LTBI has its limitations. The objective...
of 3
Get Alerted
Add your email address to receive forthcoming issues of this journal.
